テキストサイズ

  • テキストサイズ 中
  • テキストサイズ 大

JP

検索

EN

Menu

閉じる

呼吸器内科学/内科学教室(呼吸器内科学部門)

呼吸器内科学HP http://kokyu-kpum.com/

大学院科目名 呼吸器内科学
医学部教室名 内科学教室(呼吸器内科学部門)
スタッフ
教授  髙山 浩一
 
 
准教授     内野  順治
病院准教授   山田  忠明
助教            金子  美子
助教      岩破 將博
助教        森本 吉恵
研究内容 肺癌の薬物療法
研究業績
Mouri T, Naito T, Morikawa A, Tatematsu N, Miura S, Okayama T, Omae K, Takayama K.Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer Program. Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):383-390.
 
Uchino J, Nakao A, Tamiya N, Kaneko Y, Yamada T, Yoshimura K, Fujita M, Takayama K.Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. Medicine (Baltimore). 97:e11081, 2018
 
Yoshimura A, Uchino J, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Takeda T, Hiranuma O, Hasegawa I, Kubota Y, Shiotsu S, Takumi C, Hiraoka N, Yamada T, Takayama K.
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. Medicine (Baltimore). 97:e12660, 2018
 
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K,Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T.A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer. 126: 41-47, 2018
 
Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.BMC Cancer. 18: 1241, 2018
 
Nakao A, Uchino J, Igata F, On R, Ikeda T, Yatsugi H, Hirano R, Sasaki T, Tanimura K, Imabayashi T, Tamiya N, Kaneko Y, Yamada T, Nagata N, Watanabe K, Kishimoto J, Takayama K, Fujita M.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. Invest New Drugs. 36(5):903-910, 2018.
 
 
Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K.
A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer. 2019 May 31;19(1):528.
 
Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K.
 Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). Lung Cancer. 2019 Jun;132:1-8
 
Kunikane H, Yokota I, Katakami N, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Ohashi Y, Eguchi K.
Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13). Oncol Lett. 2019 Jan;17(1):1320-1326
 
Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, Ishikawa T, Takayama K, Taguchi T.
Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer. 2019 Jul;27(7):2673-2677.
 
Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, Yamaguchi T, Morikawa A, Mori N, Takahashi T, Strasser F, Omae K, Mori K, Takayama K.
Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):73-83.
 
Chihara Y, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.Invest New Drugs. 37: 291-296, 2019
 
Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.A phase II study of S-1 and Paclitaxel Combination Therapy as a First-line Treatment in Elderly Patients with Advanced Non-Small Cell lung cancer. The Oncologist. 24:459-e131, 2019
 
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.Nat Commun. 10: 259, 2019
 
Katayama Y, Yamada T, Tanimura K, Yoshimura A, Takeda T, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Thoracic Cancer. 10:526-532, 2019
 
Yoshimura A, Yamada T, Tsuji T, Hamashima R, Shiotsu S, Yuba T, Takumi C, Uchino J, Hiraoka N, Takayama K.Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. Thoracic Cancer. 10:557-563, 2019
 
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.Epithelial-to-mesenchymal Transition is a Mechanism of ALK inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.Cancer Res. 79:1658-1670, 2019
 
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.Oncologist. 2019 May;24(5):593-e170. doi: 10.1634/theoncologist.2019-0003. Epub 2019 Jan 16.
 
Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S.
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.Mol Cancer Ther. 18:947-956, 2019
 
Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K.
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Medicine. 8:1521-1529, 2019
 
Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer. 14:1061-1076, 2019
 
Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K.Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).Clinical Lung Cancer. 20:e402-e406, 2019
 
Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. Cancers. 11:282, 2019
Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.Neovascularization and tumor microenvironment: Developments in therapeutics. Cancers(Basl). 11:316, 2019
 
Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.Tumor Neovascularization and Developments in Therapeutics. Cancers (Basel). 6;11(3). pii: E316, 2019.
 
Yoshimura A, Yamada T, Okura N, Takeda T, Hirose K, Kubota Y, Shiotsu S, Hiranuma O, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers.11:365, 2019
 
Imabayashi T, Uchino J, Yoshimura A, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers (Basel). 11: 410, 2019
 
Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, Tanimura K, Harita S,Imabayashi T, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.. 8:450, 2019
 
Chihara Y, Yoshimura A, Date K, Takemura Y, Tamiya N, Kohno Y,Imabayashi T, Takeuchi M, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. The Oncologist. 24:1033-e617, 2019
 
Yoshimura A, Uchino J, Hasegawa K, Tsuji T, Shiotsu S, Yuba T, Takumi C, Yamada T, Takayama K, Hiraoka N.Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. Transl Lung Cancer Res. 8:227-234, 2019.
 
 
Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Goto H, Yoneda H, Kanematsu T, Kubota Y, Chihara Y, Harada T, Shiotsu S, Uchino J, Nishioka Y, Takayama K.Clinical significance of PD-L1 expression for patients with advanced non-small cell lung cancer treated with docetaxel and ramucirumab. Transl Lung Cancer Res. 8:450-460, 2019
 
Iwasaku M, Uchino J, Yamada T, Chihara Y, Shimamoto T, Tamiya N, Kaneko Y, Kiyomi F, Takayama K.
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). Transl Lung Cancer Res. 8:519-523, 2019
 
Yoshimura A, Yamada T, Miyagawa A, Sonobe Y, Imabayashi T, Yamada T, Okada S, Chihara Y, Iwasaku M, Kaneko Y, Uchino J, Inoue M, Konishi E, Takayama K.Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer. 137:108-112, 2019
 
Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K.Clinical features of immune‑related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD‑1 blockade.Oncology Letters 18: 2140-2147, 2019
 
Takayama K, Ichiki M, Tokunaga S, Inoue K, Kawasaki M, Uchino J, Nakanishi Y.Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
Oncologist. pii: theoncologist.2019-0513, 2019
 
Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.Transl Lung Cancer Res. 8:450-460, 2019
 
Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K.
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.Clin Transl Oncol. doi: 10.1007/s12094-019-02214-8, 2019
 
Kida T, Tanaka T, Yokota I, Tamagaki K,  Sagawa T, Kadoya M, Yamada T,  Fujioka K, Wada M, Kohno M, Hiraoka N, Omoto A,  Fukuda W, Kawahito Y.
Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study. Modern Rheumatology. 1: 1-7, 2019
 
Onoi K, Kaneko Y, Uchino J.Osimertinib in first line setting: for Asian patients. Transl Lung Cancer Res. 8:(4):550-552, 2019
 
Iwasaku M, Tanaka S, Shinzawa M, Kawakami K.
Impact of underlying chronic adrenal insufficiency on clinical course of hospitalized patients with adrenal crisis: A nationwide cohort study. Eur J Intern Med. 64:24-28, 2019
 
Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.
Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer.In Vivo. 33(1):163-166, 2019
 
Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O.
Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathway in lung cancer cells. Biochemical and Biophysical Research Communications. 507:330-336, 2018
 
問い合わせ先 TEL:075-251-5513
FAX:075-251-5376
e-mail:takayama@koto.kpu-m.ac.jp
教室独自のHP http://kokyu-kpum.com/

〒602-8566. 京都市上京区河原町通広小路上る梶井町465

お問い合わせ先
TEL:075-251-5111
FAX:075-211-7093